Improvement in the Selection of Patients for Anti-PD1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) Analyzing Tumor Mutational Burden and Retrotransposon Activity as Possible New Biomarker of Effectiveness | Publicación